Substrate Specificity Determinants in Cancer-related Solute Carrier Transporters
Substrate Specificity Determinants in Cancer-related Solute Carrier Transporters
批准号:
8827385
负责人:
Avner Schlessinger
金额:
$31.47万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2019-03-31
关键词:
AffinityAllyAmino Acid TransporterAntineoplastic AgentsBindingBiochemical PathwayBiologicalBiological AssayBiomassCell LineCell ProliferationCell membraneCellsChemicalsCodeComplexDataDatabasesDrug PrescriptionsDrug TargetingEssential Amino AcidsFamilyGenetic VariationGlioblastomaGliomaGlucose TransporterGoalsHealthHumanIndividualLaboratoriesLifeLigand BindingLigandsMalignant NeoplasmsManualsMapsMediatingMembraneMembrane ProteinsMembrane Transport ProteinsMetabolic PathwayMetabolismMethodsModelingMolecularMovementMutationNormal CellNutrientOrganellesPathogenesisPathway interactionsPharmaceutical PreparationsPlayPoint MutationProcessProteinsRoleSLC2A1 geneSideSignaling MoleculeSingle Nucleotide PolymorphismSiteSpecificityStructural ModelsStructureSubstrate SpecificityTestingToxinUniversitiesValidationVariantWorkbasecancer cellcell transformationcomparativedesignmolecular dynamicsneoplastic cellnovelprogramsrapid growthresearch studyscreeningsmall moleculesolutetooltumor metabolismuptakevirtual
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Alterations in cell metabolism support rapid growth and proliferation of cells - key hallmarks of cancer. Solute Carrier (SLC) transporters are membrane proteins that mediate the movement of solutes such as metabolites and drugs across membranes, and can also function cooperatively in cancer metabolism pathways. For exam- ple, the amino acid transporters LAT-1 and ASCT2 are highly upregulated in glioma, where they play a key role in supplying growing tumor cells with essential amino acids that are used as nutrients to build biomass and signaling molecules to enhance proliferation. Our broad goal is to understand cancer mechanisms, by de- scribing the substrate specificity determinants in selected cancer-related transporter families via an integrated experimental and computational approach. First, we will identify novel ligands including endogenous metabolites and prescription drugs for three cancer- related SLC transporters (i.e., GLUT1, ASCT2, and LAT-1), using comparative modeling, virtual screening, and chemoinformatics methods, followed by experimental validation (performed by collaborators). The results obtained in this Aim will reveal unknown functions of the transporters and provide novel chemical tools to further characterize their functions. Second, we will define rules for substrate specificity of structurally related transporters, using structural comparison methods and analysis of the predicted transporter-ligand complexes. The specificity determinants will be used to rationalize and predict the impact of genetic variation on trans- porter function. Third, we will develop methods to rationally design
polypharmacological ligands for transporters in cancer-metabolism pathways and examine the anti-proliferative effect of the discovered ligands on glioblastoma multiforme (GBM) cell lines. We will further establish the role of the transporters and their ligands in cancer, by predicting previously unknown protein-small molecule interactions via chemical similarity methods. Finally, based on our results, we will rationalize differences and commonalities between metabolic pathways of normal and transformed cells. Characterizing the interactions between key membrane transporters and their small molecule ligands will con- tribute to our understanding of how solutes get transported across the membranes of cells and organelles, which is essential for many of life's processes. Furthermore, describing substrate specificity in proteins important for cancer metabolism will provide chemical tools that would allow us to understand how perturbed metabolic networks are related to cancer and to discover novel leads for designing small molecules with optimized affinities against novel cancer drug targets. Ultimately, the results obtained in our studies can be a significant step toward designing cancer drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying New Astrocytic Kir4.1 Channel Modulators for Treating Huntington's Disease
-
批准号:10681097
-
项目类别:
-
资助金额:$25.35万
-
财政年份:2023
-
负责人:Avner Schlessinger
-
依托单位:
Substrate Specificity Determinants in Nutrient Solute Carrier Transporters
-
批准号:10735432
-
项目类别:
-
资助金额:$43.78万
-
财政年份:2023
-
负责人:Avner Schlessinger
-
依托单位:
Substrate Specificity Determinants in Nutrient Solute Carrier Transporters
-
批准号:10159939
-
项目类别:
-
资助金额:$37.69万
-
财政年份:2014
-
负责人:Avner Schlessinger
-
依托单位:
Substrate Specificity Determinants in Nutrient Solute Carrier Transporters
-
批准号:10381521
-
项目类别:
-
资助金额:$37.69万
-
财政年份:2014
-
负责人:Avner Schlessinger
-
依托单位:
Substrate Specificity Determinants in Cancer-related Solute Carrier Transporters
-
批准号:9247714
-
项目类别:
-
资助金额:$31.47万
-
财政年份:2014
-
负责人:Avner Schlessinger
-
依托单位:
Substrate Specificity Determinants in Cancer-related Solute Carrier Transporters
-
批准号:8613172
-
项目类别:
-
资助金额:$32.78万
-
财政年份:2014
-
负责人:Avner Schlessinger
-
依托单位:
Description of substrate specificity determinants in Solute Carrier Transporters
-
批准号:8062035
-
项目类别:
-
资助金额:$5.3万
-
财政年份:2010
-
负责人:Avner Schlessinger
-
依托单位:
Description of substrate specificity determinants in Solute Carrier Transporters
-
批准号:7911487
-
项目类别:
-
资助金额:$5.05万
-
财政年份:2010
-
负责人:Avner Schlessinger
-
依托单位:
Integrated Training in Pharmacological Sciences
-
批准号:10642793
-
项目类别:
-
资助金额:$27.31万
-
财政年份:2001
-
负责人:Avner Schlessinger
-
依托单位:
海外基金